Ransi Somaratne

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Marc P. Bonaca, Patrice Nault, Robert P. Giugliano et al. · Circulation · 2017 · 754 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Frederick J. Raal, Robert C. Scott, Ransi Somaratne et al. · Circulation · 2012 · 503 citations

Life Sciences, Cardiology, Pharmacotherapy +17

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

Robert P. Giugliano, Nihar R. Desai, Payal Kohli et al. · The Lancet · 2012 · 424 citations

Pharmacy, Internal Medicine, Pharmacotherapy +10

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia

Michael J. Koren, Robert P. Giugliano, Frederick J. Raal et al. · Circulation · 2013 · 216 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17